BREAKWATER trial

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

BREAKWATER trial

Feb 2, 2025, 04:22 | Blog

Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology…

Feb 1, 2025, 07:52 | Insight

Shaalan Beg: Poll Insights on BREAKWATER Trial Results

Shaalan Beg, Senior Advisor for Clinical Research at the National Cancer Institute, posted the following…

Dec 22, 2024, 06:53 | Insight

FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer

On December 20, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to…

All: 3 Posts: 1 - 100

'

ASCO 2025 for Trainees and Residents: Your Ultimate Guide to Success

'

ctDNA after surgery for MMRd tumors can prevent cancer recurrence - Yelena Janjigian at AACR25

'

Top Growing Medical Universities in the Post-Soviet Region – BIGR 2025 Edition

'

Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab

'

POEM 2025 Scientific Meeting: Key Sessions, Workshops, and Why You Should Attend

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023